Sutro Biopharma, Inc.
STRO
$30.52
$0.973.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 49.94% | 65.18% | -34.36% | -38.31% | -56.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.94% | 65.18% | -34.36% | -38.31% | -56.88% |
| Cost of Revenue | -41.44% | -53.54% | -35.47% | -20.42% | -0.23% |
| Gross Profit | 87.78% | 92.31% | 37.88% | -41.47% | -198.85% |
| SG&A Expenses | -27.91% | -15.34% | -26.39% | -17.82% | -18.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.87% | -30.97% | -16.77% | -1.98% | 14.77% |
| Operating Income | 62.02% | 55.99% | -5.01% | -56.00% | -121.30% |
| Income Before Tax | 36.70% | 15.07% | -98.29% | -93.22% | -149.95% |
| Income Tax Expenses | -104.85% | -103.94% | -85.18% | -86.72% | -86.68% |
| Earnings from Continuing Operations | 37.36% | 15.99% | -74.88% | -67.70% | -113.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.36% | 15.99% | -74.88% | -67.70% | -113.31% |
| EBIT | 62.02% | 55.99% | -5.01% | -56.00% | -121.30% |
| EBITDA | 63.78% | 57.78% | -4.90% | -59.51% | -129.62% |
| EPS Basic | 44.55% | 24.73% | -58.28% | -35.41% | -56.12% |
| Normalized Basic EPS | 58.39% | 51.95% | -3.05% | -26.12% | -55.87% |
| EPS Diluted | 44.55% | 24.73% | -58.28% | -35.41% | -56.12% |
| Normalized Diluted EPS | 58.39% | 51.95% | -3.05% | -26.12% | -55.87% |
| Average Basic Shares Outstanding | 16.90% | 10.03% | 18.22% | 26.75% | 36.25% |
| Average Diluted Shares Outstanding | 16.90% | 10.03% | 18.22% | 26.75% | 36.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |